AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8393108
Drug: Doxycycline (Do)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (Do) 200 mg on the first day and 100 mg for 4 days, followed by Amoxicillin/Clavulanate potassium (Au) 500 mg 3 times daily for 5 days
Trial: 27048836
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplementation of pasteurised Bacteroides xylanisolvens DSM 23964 for 8 weeks
Trial: 24502652
Drug: Short-term professional
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term professional oral health care (once per week for 1 month)
Trial: 23564179
Drug: Oxytocin 40
RxNorm normalized name: oxytocin 40 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 40 IU nasal spray
Trial: 18847422
Drug: Biocompatible bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible bicarbonate solution
Trial: 18847422
Drug: Biocompatible lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible lactate solution
Trial: 18847422
Drug: Bicarbonate/lactate solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/lactate solutions
Trial: 25746151
Drug: Biocompatible solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible solutions
Trial: 18847422
Drug: New solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New solutions
Trial: 18847422
Drug: Dialysis solutions
RxNorm normalized name: dialysis solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis solutions with higher glucose degradation products
Trial: 16635293
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment group (100 mg orally every day)
Trial: 16635293
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional supporting treatment)
Trial: 16635293
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment group
Trial: 12583554
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g)
Trial: 10980913
Drug: Low-dose fish
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fish oil (875 mg capsules containing 850 to 882 mg EPA and DHA)
Trial: 3928960
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide with forced diuresis (Group A)
Trial: 3928960
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide without forced diuresis (Group B)
Trial: 9177376
Drug: Tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 1.25 mg (n = 36, 29 completed)
Trial: 9177376
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg (n = 35, 28 completed)
Trial: 8257146
Drug: Rufloxacin taken
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rufloxacin taken 5 min after antacid (Maalox 30 ml)
Trial: 8257146
Drug: Rufloxacin taken
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rufloxacin taken 4 h before antacid (Maalox 30 ml)
Trial: 4041513
Drug: nonsedating doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonsedating doses of diazepam
Trial: 30231626
Drug: erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab 70 mg
Trial: 30231626
Drug: erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab 140 mg
Trial: 30253049
Drug: all-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all-trans retinoic acid/Clobetasol Propionate Compound Ointment
Trial: 30253049
Drug: calcipotriol/betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcipotriol/betamethasone dipropionate ointment
Trial: 26559681
Drug: B9 (10mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B9 (10mg/day orally) for 2 months, followed by B12 (1000 μg) for 2 months, then B9 + B12 for 2 months (Group A)
Trial: 21088807
Drug: L‐T4 replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 replacement
Trial: 17389557
Drug: darunavir (TMC114)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darunavir (TMC114) coadministered with low-dose ritonavir under fasted conditions
Trial: 17389557
Drug: darunavir (TMC114)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darunavir (TMC114) coadministered with low-dose ritonavir after a standard meal
Trial: 16372585
Drug: Sparfloxacin (SPFX)
DrugBank: Sparfloxacin (DB01208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (SPFX) 200 mg/day for 21 days
Trial: 16372585
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment for 21 days
Trial: 11953688
Drug: Octreotide 500
RxNorm normalized name: 1 ML octreotide 500 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 500 microg thrice daily
Trial: 9621317
Drug: Ultraviolet laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet laser therapy (UVLT)
Trial: 1890604
Drug: AL 721
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL 721 (20, 30, 40, or 50 g orally twice daily for 8 weeks)
Trial: 367411
Drug: Cyclizine 100
RxNorm normalized name: cyclizine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine 100 mg
Trial: 17042842
Drug: Cyclizine 50
RxNorm normalized name: cyclizine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine 50 mg
Trial: 11497156
Drug: High-volume haemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume haemofiltration (HVHF; 6 l/h)
Trial: 11497156
Drug: Standard continuous
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard continuous veno-venous haemofiltration (CVVH; 1 l/h)
Trial: 11497156
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (HVHF and CVVH)
Trial: 8221579
Drug: Daunorubicin infusion
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin infusion
Trial: 24915899
Drug: FOLFIRI+PB (panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI+PB (panitumumab 3 mg/kg and bevacizumab 3 mg/kg plus FOLFIRI every other week)
Trial: 12689743
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Doxazosin and Finasteride
Trial: 10476945
Drug: Sublingual human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual human interferon-alpha (IFN-alpha) 15 IU
Trial: 10476945
Drug: Sublingual human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual human interferon-alpha (IFN-alpha) 150 IU
Trial: 12057718
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg twice daily)
Trial: 8701785
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (100 mg on days 5-14 of the menstrual cycle)
Trial: 6418100
Drug: Quinidine (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (700 to 1100 mg/day)
Trial: 6168848
Drug: Disopyramide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (600 mg/day)
Trial: 29753661
Drug: Protocol 1
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1 (P1) with 120 kVp, 180mAs, and 100mL of contrast agent with filtered back‐projection (FBP)
Trial: 29753661
Drug: Protocol 2
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2 (P2) with 80 kVp, 140mAs and 75mL of contrast agent with hybrid iterative reconstruction
Trial: 29753661
Drug: Protocol 3
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 3 (P3) with 80 kVp, 140mAs and 75mL of contrast agent with iterative model reconstruction (IMR)
Trial: 11996209
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A
Trial: 11996209
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B
Trial: 7714743
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C
Trial: 15998607
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control group without access to the ODIN website (n = 100)
Trial: 8597466
Drug: DHEA 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 300 mg, orally three times daily for 14 days
Trial: 8597466
Drug: Placebo capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, orally three times daily for 14 days
Trial: 2548905
Drug: 0.25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 micrograms alpha‐calcoid given orally twice daily (n = 9)
Trial: 23769863
Drug: Inhaled extra-fine
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled extra-fine beclomethasone/formoterol (I‐EF‐BDP/F)
Trial: 17175304
Drug: Sirolimus-based calcineurin
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus-based calcineurin inhibitor (CNI)-free regimen (sirolimus 5 mg daily starting postoperative day 3, mycophenolate mofetil 1 gm twice a day, methylprednisolone 500 mg intraoperatively, prednisone 30 mg daily tapered to 10 mg daily at 3 months)
Trial: 17175304
Drug: Tacrolimus-based steroid-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus-based steroid-free regimen (tacrolimus 0.075 mg/kg twice a day, mycophenolate mofetil 1 g twice a day, methylprednisolone 500 mg, 250 mg, and 125 mg from days 0 to 2, then no further steroids)
Trial: 27929346
Drug: d-amphetamine 0
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 0 mg (placebo)
Trial: 7285484
Drug: d-amphetamine 5
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 5 mg
Trial: 21894485
Drug: d-amphetamine 20
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 20 mg
Trial: 12927652
Drug: d-amphetamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (all doses)
Trial: 10620000
Drug: Nitroglycerin-releasing 'active'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin-releasing 'active' patches (approx. 0.4 mg hour‐1 nitroglycerin)
Trial: 8620093
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal therapy (Zemaphyte) for 8 weeks
Trial: 8620093
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal therapy (Zemaphyte)
Trial: 3919754
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream containing 4% sodium cromoglycate (SCG)
Trial: 24946630
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group used triamcinolone acetonide cream externally and locally, twice a day for 15 days.
Trial: 24946630
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups underwent treatment for 3 sessions, with hemorheology tests and radioimmunoassays for IL-2, IL-6, IL-10, and TNF-alpha levels.
Trial: 18041396
Drug: Noninvasive Mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Trial: 18041396
Drug: Invasive Mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Trial: 18041396
Drug: Noninvasive Mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Trial: 18041396
Drug: Invasive Mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Trial: 16116046
Drug: Valsartan/Hydrochlorothiazide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Hydrochlorothiazide (160 mg/12.5 mg)
Trial: 8584772
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with fentanyl (10 micrograms/kg initial dose, followed by 5 micrograms/kg/h infusion)
Trial: 2236433
Drug: beta‐adrenoceptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐adrenoceptor blockade (100 mg of atenolol)
Trial: 486932
Drug: High-nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-nicotine cigarettes (1.84 mg standard yield)
Trial: 486932
Drug: Low-nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-nicotine cigarettes (0.6 mg standard yield)
Trial: 486932
Drug: Medium-nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-nicotine cigarettes (1.4 mg standard yield)
Trial: 30497684
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 750-1000 mg/m2 daily
Trial: 30497684
Drug: Levamisole 2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2-2.5 mg/kg on alternate days
Trial: 27986549
Drug: Clinical treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical treatment (Control group)
Trial: 25504994
Drug: Nintedanib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 50 mg twice daily for 14 days
Trial: 25504994
Drug: Nintedanib 100
RxNorm normalized name: nintedanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 100 mg twice daily for 14 days
Trial: 25504994
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg twice daily for 28 days
Trial: 25504994
Drug: Nintedanib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib added to ongoing pirfenidone therapy
Trial: 20135132
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg estradiol vaginal tablets (group I)
Trial: 20135132
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyaluronic acid sodium salt vaginal tablets (group II)
Trial: 16734312
Drug: Prompt‐L‐Pop with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop with Dyract Seal
Trial: 16734312
Drug: Prompt‐L‐Pop with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop with Concise
Trial: 16734312
Drug: Prompt‐L‐Pop with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop with Visio‐Seal
Trial: 16734312
Drug: Prompt‐L‐Pop with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop with Helioseal
Trial: 15119985
Drug: Quality assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality assessment of meta-analyses of RCTs of pharmacotherapy for MDD
Trial: 11402910
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg for 4 weeks
Trial: 11402910
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 16 mg for 4 weeks
Trial: 21050239
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 treatment
Trial: 29522710
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d vitamin C as a twice daily bolus infusion
Trial: 29522710
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d vitamin C as continuous infusion
Trial: 29522710
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d vitamin C as a twice daily bolus infusion
Trial: 29522710
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d vitamin C as continuous infusion
Trial: 29522710
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d vitamin C (all regimens)
Trial: 29522710
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d vitamin C (all regimens)
Trial: 29522710
Drug: Post-discontinuation of
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation of vitamin C
Trial: 25969567
Drug: Lifestyle changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle changes and guideline-based treatment according to ADA recommendations
Trial: 22585884
Drug: Pedometer step‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer step‐based Green Prescription
Trial: 22585884
Drug: Standard Green
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Green Prescription
Trial: 17645076
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser radiation of blood (ILRB)
Trial: 17645076
Drug: Antioxidant drug
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant drug cytoflavin
Trial: 12440352
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (vitamin E 600 mg/day, vitamin C 250 mg/day, betacarotene 20 mg/day)
Trial: 9019387
Drug: Etidocaine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidocaine (15 mg/ml)
Trial: 9019387
Drug: Bupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (5 mg/ml) + Lidocaine (10 mg/ml)
Trial: 29169838
Drug: Lidocaine (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (260 mg of 2% lidocaine subcutaneously and intratesticularly 5 minutes prior to castration)
Trial: 29169838
Drug: Meloxicam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (0.5 mg kg−1 of meloxicam subcutaneously 30 minutes prior to castration)
Trial: 29169838
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative analgesia administered)
Trial: 26512601
Drug: Peginterferon/ribavirin (P‐R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon/ribavirin (P‐R) treatment
Trial: 15476908
Drug: Tobramycin 3
RxNorm normalized name: tobramycin 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 3 mg/mL plus dexamethasone 1 mg/mL (TD)
Trial: 15476908
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL (DNP)
Trial: 15476908
Drug: Neomycin sulfate
RxNorm normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL (NPG)
Trial: 11902023
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy group
Trial: 9493884
Drug: Daily inner
RxNorm normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily inner cannula changes